Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

For PASG, shares are up 24.26% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 3.78% over the same time period.

Passage Bio (PASG) stock soars as the company out-licenses gene therapy programs targeting pediatric lysosomal storage diseases to GEMMA Biotherapeutics. Read more here.

Passage Bio, Inc. PASG could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average ...

In a report released on February 24, Yun Zhong from BTIG maintained a Buy rating on Passage Bio (PASG – Research Report), with a price target of $9.00. The company’s shares closed last Friday ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...